JP2008540661A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540661A5 JP2008540661A5 JP2008512394A JP2008512394A JP2008540661A5 JP 2008540661 A5 JP2008540661 A5 JP 2008540661A5 JP 2008512394 A JP2008512394 A JP 2008512394A JP 2008512394 A JP2008512394 A JP 2008512394A JP 2008540661 A5 JP2008540661 A5 JP 2008540661A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- ring
- optionally substituted
- compound
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 34
- -1 1,2-methylenedioxy Chemical group 0.000 claims 20
- 125000005843 halogen group Chemical group 0.000 claims 19
- 125000001931 aliphatic group Chemical group 0.000 claims 18
- 125000001424 substituent group Chemical group 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 208000002193 Pain Diseases 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 125000002723 alicyclic group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 208000008035 Back Pain Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 208000005298 acute pain Diseases 0.000 claims 3
- 125000001118 alkylidene group Chemical group 0.000 claims 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 208000000003 Breakthrough pain Diseases 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000004404 Intractable Pain Diseases 0.000 claims 2
- 206010028836 Neck pain Diseases 0.000 claims 2
- 208000004550 Postoperative Pain Diseases 0.000 claims 2
- 208000008765 Sciatica Diseases 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 230000002981 neuropathic effect Effects 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- MCRAICCHFJHVDC-UHFFFAOYSA-N n-(4-cyano-3-methylsulfanyl-1h-pyrazol-5-yl)-1-methyl-2-oxo-4-(trifluoromethyl)quinoline-6-sulfonamide Chemical compound CSC1=NNC(NS(=O)(=O)C=2C=C3C(=CC(=O)N(C)C3=CC=2)C(F)(F)F)=C1C#N MCRAICCHFJHVDC-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000015706 neuroendocrine disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 claims 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 claims 1
- 0 C*(C)(*)C1SC=NN1 Chemical compound C*(C)(*)C1SC=NN1 0.000 description 2
- WCUMFMHNYNLLBE-UHFFFAOYSA-N Cc1n[s]nc1 Chemical compound Cc1n[s]nc1 WCUMFMHNYNLLBE-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N c1cncnc1 Chemical compound c1cncnc1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68151905P | 2005-05-16 | 2005-05-16 | |
| PCT/US2006/018669 WO2006124744A1 (en) | 2005-05-16 | 2006-05-12 | Bicyclic derivatives as modulators of ion channels |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012074138A Division JP2012126744A (ja) | 2005-05-16 | 2012-03-28 | イオンチャネルのモジュレーターとしての二環式の誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008540661A JP2008540661A (ja) | 2008-11-20 |
| JP2008540661A5 true JP2008540661A5 (enExample) | 2009-07-02 |
Family
ID=36915025
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008512394A Ceased JP2008540661A (ja) | 2005-05-16 | 2006-05-12 | イオンチャネルのモジュレーターとしての二環式の誘導体 |
| JP2012074138A Withdrawn JP2012126744A (ja) | 2005-05-16 | 2012-03-28 | イオンチャネルのモジュレーターとしての二環式の誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012074138A Withdrawn JP2012126744A (ja) | 2005-05-16 | 2012-03-28 | イオンチャネルのモジュレーターとしての二環式の誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7745629B2 (enExample) |
| EP (1) | EP1888558B1 (enExample) |
| JP (2) | JP2008540661A (enExample) |
| KR (1) | KR20080021030A (enExample) |
| CN (1) | CN101218226A (enExample) |
| AT (1) | ATE527251T1 (enExample) |
| AU (1) | AU2006247478A1 (enExample) |
| CA (1) | CA2608599A1 (enExample) |
| IL (1) | IL187382A0 (enExample) |
| MX (1) | MX2007014486A (enExample) |
| NO (1) | NO20076447L (enExample) |
| RU (1) | RU2007146769A (enExample) |
| WO (1) | WO2006124744A1 (enExample) |
| ZA (1) | ZA200710332B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615563B2 (en) * | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| ZA200709961B (en) | 2005-05-10 | 2009-07-29 | Vertex Pharma | Bicyclic derivatives as modulators of ion channels |
| NZ567132A (en) * | 2005-09-09 | 2011-12-22 | Vertex Pharma | Bicyclic derivatives as modulators of voltage gated ion channels |
| AU2006306367A1 (en) * | 2005-10-21 | 2007-05-03 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
| EP2308872A1 (en) * | 2005-12-21 | 2011-04-13 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| WO2008101029A2 (en) * | 2007-02-13 | 2008-08-21 | Xenon Pharmaceuticals Inc. | Use of thiazole, oxazole and imidazole compounds for the treatment of sodium channel-mediated diseases or conditions |
| EP2158183A2 (en) | 2007-05-25 | 2010-03-03 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| US7994174B2 (en) * | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| EP2205079A4 (en) * | 2007-10-04 | 2010-10-27 | Merck Sharp & Dohme | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS |
| CA2705336A1 (en) | 2007-11-13 | 2009-05-22 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| RU2010123876A (ru) * | 2007-11-13 | 2011-12-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероциклические производные в качестве модуляторов ионных каналов |
| CN101978787A (zh) * | 2008-04-30 | 2011-02-16 | 夏普株式会社 | 照明装置和显示装置 |
| CN102099356A (zh) * | 2008-07-01 | 2011-06-15 | 沃泰克斯药物股份有限公司 | 用作离子通道调节剂的杂环衍生物 |
| CA2797694A1 (en) | 2010-04-29 | 2011-11-03 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Activators of human pyruvate kinase |
| WO2013086229A1 (en) | 2011-12-07 | 2013-06-13 | Amgen Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| WO2014201173A1 (en) | 2013-06-12 | 2014-12-18 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| BR112016017996A2 (pt) | 2014-02-06 | 2017-08-08 | Abbvie Inc | 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| US12234221B2 (en) | 2018-07-09 | 2025-02-25 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting NAV1.8 |
| SG11202100137TA (en) | 2018-07-09 | 2021-02-25 | Lieber Institute Inc | PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8 |
| IL288802B2 (en) | 2019-06-18 | 2025-08-01 | Pfizer | Benzisoxazole sulfonamide derivatives |
| JP7739051B2 (ja) | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| CN115073370B (zh) * | 2021-03-10 | 2024-12-17 | 成都硕德药业有限公司 | 新型烷基氨类化合物或盐、异构体、其制备方法及用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US5869478A (en) * | 1995-06-07 | 1999-02-09 | Bristol-Myers Squibb Company | Sulfonamido substituted benzopyran derivatives |
| WO1999009983A1 (en) | 1997-08-28 | 1999-03-04 | Bristol-Myers Squibb Company | 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators |
| GB0217431D0 (en) * | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| US7157577B2 (en) * | 2003-03-07 | 2007-01-02 | Sugen Inc. | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors |
| US7009052B2 (en) * | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
| CA2539227A1 (en) | 2003-08-08 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| US7615563B2 (en) | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
| ZA200709961B (en) | 2005-05-10 | 2009-07-29 | Vertex Pharma | Bicyclic derivatives as modulators of ion channels |
| CA2611731A1 (en) | 2005-06-09 | 2006-12-14 | Vertex Pharmaceuticals Incorporated | Indane derivatives as modulators of ion channels |
| NZ567132A (en) | 2005-09-09 | 2011-12-22 | Vertex Pharma | Bicyclic derivatives as modulators of voltage gated ion channels |
| AU2006304283B2 (en) | 2005-10-12 | 2012-01-19 | Vertex Pharmaceuticals Incorporated | Biphenyl derivatives as modulators of voltage gated ion channels |
| AU2006306367A1 (en) | 2005-10-21 | 2007-05-03 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
| EP2308872A1 (en) | 2005-12-21 | 2011-04-13 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| US7994174B2 (en) | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
| CA2705336A1 (en) | 2007-11-13 | 2009-05-22 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| RU2010123876A (ru) | 2007-11-13 | 2011-12-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероциклические производные в качестве модуляторов ионных каналов |
| US8697739B2 (en) * | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
-
2006
- 2006-05-12 EP EP06770340A patent/EP1888558B1/en not_active Not-in-force
- 2006-05-12 JP JP2008512394A patent/JP2008540661A/ja not_active Ceased
- 2006-05-12 MX MX2007014486A patent/MX2007014486A/es not_active Application Discontinuation
- 2006-05-12 RU RU2007146769/04A patent/RU2007146769A/ru not_active Application Discontinuation
- 2006-05-12 US US11/432,997 patent/US7745629B2/en active Active
- 2006-05-12 KR KR1020077029355A patent/KR20080021030A/ko not_active Withdrawn
- 2006-05-12 AT AT06770340T patent/ATE527251T1/de not_active IP Right Cessation
- 2006-05-12 ZA ZA200710332A patent/ZA200710332B/xx unknown
- 2006-05-12 AU AU2006247478A patent/AU2006247478A1/en not_active Abandoned
- 2006-05-12 WO PCT/US2006/018669 patent/WO2006124744A1/en not_active Ceased
- 2006-05-12 CN CNA2006800252561A patent/CN101218226A/zh active Pending
- 2006-05-12 CA CA002608599A patent/CA2608599A1/en not_active Abandoned
-
2007
- 2007-11-15 IL IL187382A patent/IL187382A0/en unknown
- 2007-12-14 NO NO20076447A patent/NO20076447L/no not_active Application Discontinuation
-
2010
- 2010-04-16 US US12/761,502 patent/US8314125B2/en active Active
-
2012
- 2012-03-28 JP JP2012074138A patent/JP2012126744A/ja not_active Withdrawn
- 2012-11-16 US US13/679,028 patent/US8536195B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008540661A5 (enExample) | ||
| KR101979042B1 (ko) | 세린/트레오닌 키나제 억제제로서의 퀴나졸린 화합물 | |
| JP2009524591A5 (enExample) | ||
| JP7570235B2 (ja) | Ｓｔｉｎｇ活性化剤としての三環式複素環式化合物 | |
| RU2007146769A (ru) | Бициклические производные и их применение в качестве модуляторов ионых каналов | |
| WO2022230912A1 (ja) | 置換トリアジン化合物 | |
| KR101826371B1 (ko) | 신규 히드록삼산 유도체 | |
| JP2009511599A5 (enExample) | ||
| JP7328323B2 (ja) | ＳＭＡＲＣＡ２／ＢＲＭ ＡＴＰａｓｅ阻害剤としての尿素化合物及び組成物 | |
| RU2007145434A (ru) | Бициклические производные в качестве модуляторов ионных каналов | |
| HRP20180335T1 (hr) | Kondenzirani derivati imidazola korisni kao ido inhibitori | |
| CA2828478A1 (en) | Serine/threonine kinase inhibitors | |
| JP2008543785A5 (enExample) | ||
| RU2007148504A (ru) | Индановые производные в качестве модуляторов ионных каналов | |
| WO2000047558A1 (en) | Amide compounds and medicinal use thereof | |
| PL197181B1 (pl) | Pochodna benzamidowa, sposób jej wytwarzania, jej kompozycja farmaceutyczna i jej zastosowanie do wytwarzania leku | |
| CN1474818A (zh) | 含有稠合杂环化合物或其盐的糖尿病预防或治疗药 | |
| JP7148500B2 (ja) | 新規テトラヒドロナフチルウレア誘導体 | |
| AU2016298962B2 (en) | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | |
| JP2009507851A5 (enExample) | ||
| JP2005239670A (ja) | 含窒素複素環化合物およびその医薬用途 | |
| RU2008118350A (ru) | Бифенильные производные в качестве модуляторов потенциалзависимых ионных каналов | |
| RU2008113836A (ru) | Бициклические производные в качестве модуляторов потенциалозависимых ионных каналов | |
| JP2023533349A (ja) | Ｂｔｋ阻害剤としての化合物およびその製造方法と応用 | |
| PT1828148E (pt) | Compostos de amino benzofenona substituídos por triazol |